Ignite Creation Date:
2024-05-06 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06194448
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2023-12-20
Brief Title:
To Evaluate the EfficacySafety of Osimertinib Prior to CRT and Maintenance of it With Stage III Unresectable NSCLC With EGFR Mutations
Sponsor:
Organization:
AstraZeneca